Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020
Conference call and webcast on Tuesday, September 22 at 2:30 pm CET/8:30 am ET TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer: More than 90% of the planned 500 patients enrolled Fast-Track designation granted by U.S. FDA Interim superiority analysis expected in Q1 2021 ; final
View HTML
Toggle Summary ERYTECH establishes a financing facility with the implementation of an at-the-market program on Nasdaq with Cowen
LYON, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances in red blood cells (the "Company"), today announced the implementation of an
View HTML
Toggle Summary ERYTECH to Host on September 22, 2020 Second Quarter 2020 Conference Call and Business Update
LYON, France, Sept. 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter
View HTML
Toggle Summary ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment
More than 450 of the planned ~ 500 patients enrolled Interim superiority analysis expected around year-end 2020 Call with KOL Dr. Manuel Hidalgo on September 29, 2020 at 10:00 am ET LYON, France and CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Nov 5, 2020

Business Update and Financial Highlights for the 3rd Quarter of 2020 (after U.S. market close)

Summary Toggle Nov 6, 2020 at 8:30 AM EST

Erytech Pharma 3rd Quarter of 2020 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top